What are you looking for today?

Festuccia, Claudio, Gravina, Giovanni, Mancini, Andrea, Muzi, Paola, Cesare, Ernesto, Kirk, Ralph, Smith, Matthew, Hughes, Shaun, Gibson, Robert, Lian, Lu-Yun, Ricevuto, Enrico and Carnell, Andrew (2014) Trifluoroibuprofen Inhibits alpha-Methylacyl Coenzyme A Racemase (AMACR/P504S), Reduces Cancer Cell Proliferation and Inhibits in vivo Tumor Growth in Aggressive Prostate Cancer Models. Anti-Cancer Agents in Medicinal Chemistry, 14 (7). pp. 1031-1041. ISSN 18715206

Full text not available from this repository. (Request a copy)

Abstract

Abstract

Background: α-Methylacyl-CoA racemase (AMACR) participates in the oxidation of branched chain fatty acids and is highly expressed in prostate cancer (PCa). The aims of this study were to verify if the AMACR inhibitor trifluoroibuprofen (TFIP) had anticancer effects and to determine the best route for in vivo administration.

Materials and Methods: In vitro effects of TFIP were verified by using three non-tumour prostate epithelial cell lines, a series of eight PCa cell lines and six cell derivatives. In vivo experiments were performed using PC3 and 22rv1 xenografts grown in nude mice with TFIP administered intraperitoneally or by oral gavage.

Results: AMACR was expressed in PCa cell lines but was absent in normal and BPH cells. Although androgen-independent (AI) cell lines originating from androgen-dependent (AD) LnCaP cells displayed increased AMACR expression, the levels of this enzyme were higher in AI with respect to AD cell lines. TFIP induced: (1) down-modulation of AMACR expression; (2) suppression of the survival Akt/mTOR signalling pathway and (3) down-modulation of cyclin D1 and survivin with G2/M arrest and apoptosis. TFIP exhibited antitumour effects independently of the administration method. Nevertheless, oral administration was associated with acute toxicity at doses >75 mg/Kg/day. A dose of 75 mg/Kg administered biweekly reduced the toxicity whereas limited toxic effects were observed at 50 mg/Kg/day. Intraperitoneal administration of 75-100 mg/Kg/day was not toxic.

Conclusions: AMACR is a good pharmacological target for treatment of PCa and TFIP is a suitable anticancer compound with parenteral administration being the preferred route.

Item Type: Article
Depositing User: Matt Smith
URI: https://sure.sunderland.ac.uk/id/eprint/16346

Further Details

More Information

Depositing User

Identifiers

Item ID
16346
Identification Number
ISSN
18715206

Users with ORCIDS

ORCID for Matthew Smith

Catalogue record

Date Deposited
09 Aug 2023 13:02
Last Modified
04 Jun 2025 16:05

Contributors

Author
Claudio Festuccia
Author
Giovanni Gravina
Author
Andrea Mancini
Author
Paola Muzi
Author
Ernesto Cesare
Author
Ralph Kirk
Author
Shaun Hughes
Author
Robert Gibson
Author
Lu-Yun Lian
Author
Enrico Ricevuto
Author
Andrew Carnell

University Divisions

Subjects

Actions (login required)

View Item (Repository Staff Only)